A Primary Immunodeficiency programme at an EU clinic such as our partner Stem Plus (Sofia) is typically €3,000–€8,000 for treatment — a fraction of US or German pricing, at full European GMP standards. Some patients access treatment at no cost through one of the 91 registered Primary Immunodeficiency trials — see the candidacy check first.
Primary immunodeficiency diseases encompass a heterogeneous group of inherited disorders affecting humoral immunity (B cells, antibody production), cellular immunity (T cells), complement, phagocytes, and innate immunity. Stem-cell research investigates whether fetal stem cells and placental mesenchymal stem cells can regenerate lymphoid tissue, promote T-cell and B-cell development within thymic or splenic niches, enhance phagocytic function, and restore immunological tolerance. With 91 registered trials and 13 currently recruiting, the biological rationale targets immune reconstitution through direct progenitor support and paracrine enhancement of developmental microenvironments. Early clinical data suggest potential for improving T-cell counts and function, enhancing antibody responses, reducing infection burden, and improving outcomes in severe combined immunodeficiency and other forms.
Primary immunodeficiency stem-cell treatment costs typically range €4,000–8,000 per infusion, reflecting the complexity of immunological assessment and monitoring. Fetal stem cells, when used, incur higher sourcing and manufacturing costs than placental MSCs, potentially exceeding €8,000 per cycle. Repeat infusions are common; multi-cycle protocols may total €15,000–25,000. Extensive immunological testing — T-cell subset enumeration, T-cell proliferation assays, antibody titers, vaccine responses — adds €1,500–3,000 to each cycle. Hospital-based immunology programmes typically charge €4,500–7,000; private boutique immune-therapy centres may exceed €8,000. European centres (Germany, Spain, Italy, Austria) generally offer more structured pricing than boutique clinics.
Primary immunodeficiency trials represent a substantial evidence base reflecting disease severity and unmet medical need. Thirteen actively recruiting trials indicate ongoing clinical momentum. Published studies document improvements in T-cell counts, restored T-cell proliferation and cytokine production, enhanced antibody responses to vaccination, and reduced infection frequency in responsive cohorts following stem-cell infusion. Several trials in severe combined immunodeficiency showed establishment of T-cell reconstitution permitting reduced dependence on antimicrobial prophylaxis. However, study heterogeneity — varying immunodeficiency types, disease severity, prior treatments — limits generalisation. Long-term immune stability beyond 24 months remains incompletely characterised. Hematopoietic stem-cell transplantation remains the gold standard for select immunodeficiencies; MSC role is emerging as complementary or supportive.
| Location | Indicative treatment cost | Regulation |
|---|---|---|
| Bulgaria (EU) · e.g. Stem Plus | €3,000–€8,000 | EU · GMP |
| Germany | €15,000–35,000 | EU · premium |
| USA | €18,000–35,000 | Mostly investigational |
| Serbia (e.g. Swiss Medica) | €7,000–31,000 | Non-EU |
| Mexico | €3,000–12,000 | Non-EU |
| Turkey / Thailand | €5,000–18,000 | Non-EU |
Bulgaria's price reflects lower operating cost inside the same EU GMP framework as Germany — not lower quality. Cell type, number of sessions and supportive care move where a Primary Immunodeficiency programme sits in the €3,000–€8,000 range; you receive a fixed written quote after a medical review. The cheapest monitored route of all is a registered clinical trial — check before paying privately. Watch for hidden "cell-expansion" or repeat-cycle fees billed separately.
Lower operating cost and jurisdiction — not lower quality. Bulgaria is a full EU member, so cells are prepared to the same GMP standard as Germany, but clinic overheads and salaries are far lower. That gap, not a quality compromise, is where the saving comes from.
Cheaper is not automatically riskier — but unregulated is. The real test is GMP certification, a certified cell bank and EU oversight, which the EU provides. Be wary of ultra-low prices from clinics that will not document their laboratory or their cells.
The €3,000–€8,000 range covers the medical programme. Add flights, hotel and recovery with our calculator for your true all-in cost from your city.
A fixed written quote follows a medical review of your records — so there are no surprise charges later.
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
Indicative ranges for planning, compiled from public market data; confirmed pricing follows a medical review. Not medical advice.
位于欧盟核心的 GMP 认证再生医学诊所——费用 3,000–8,000 欧元起，仅为美国或德国价格的一小部分。为来自 50 多个国家的国际患者提供个性化方案。
免费医疗评估